 circumsporozoite protein encapsulated in oligomannose-coated liposomes confers protection against sporozoite infection in mice by unknown
Terkawi et al. Malaria Journal 2014, 13:426
http://www.malariajournal.com/content/13/1/426RESEARCH Open AccessPlasmodium berghei circumsporozoite protein
encapsulated in oligomannose-coated liposomes
confers protection against sporozoite infection
in mice
Mohamad Alaa Terkawi1, Yasuhiro Kuroda2, Shinya Fukumoto1, Sachi Tanaka1, Naoya Kojima2
and Yoshifumi Nishikawa1*Abstract
Background: The design and development of an effective malaria vaccine against the pre-erythrocytic and
erythrocytic-stages of infection present a great challenge.
Methods: In the present study, protective efficacy of oligomannose-coated liposome (OML)-entrapped merozoite
and sporozoite antigens against Plasmodium berghei challenge infection in BALB/c mice was evaluated.
Results: Subcutaneous immunization with truncated merozoite surface protein 1 entrapped with OML (OML-PbMSP1)
prolonged survival, but failed to protect the mice from erythrocytic-stage infection, despite the antigen-specific
antibody responses induced by the immunization regimen. In contrast, immunization with circumsporozoite protein
entrapped with OML (OML-PbCSP) elicited antigen-specific humoral and cellular responses, which correlated with
substantial protection against sporozoite challenge infections.
Conclusions: The current results represent the use of an oligomannose-coated liposome-based vaccine against
pre-erythrocytic and erythrocytic stages malaria infection. This approach may offer a new vaccination strategy against
malaria infection.
Keywords: Vaccine, Plasmodium berghei, Oligomannose-coated liposomeBackground
Malaria remains the most important parasitic disease of
humans, affecting 40% of the world’s population and caus-
ing over 600,000 deaths annually [1]. Vaccination to pre-
vent the infection is believed to be the most realistic
approach for reducing malaria morbidity and mortality.
Over the last decades, the gold standard for malaria vac-
cine development has been immunization with radiation-
attenuated sporozoites [1]. Recent study has shown that
genetic attenuated sporozoites by gene deletion may offer
better strategy for development of malaria vaccine [2].
Although this vaccine strategy offers sterile protection* Correspondence: nisikawa@obihiro.ac.jp
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unless otherwise stated.against infection, several problems exist that have ham-
pered its use including the cost, dose standardization, pro-
duction, sporozoite irradiation, and immunization-related
issues [3,4].
The most advanced malaria vaccine to date, RTS,S, com-
prises a portion of the Plasmodium falciparum circumspor-
ozoite protein (CSP) central repeat (NANP) and C-terminal
region, which contains T cell epitopes fused to the hepatitis
B virus surface antigen. Since early 1996, several adjuvant
formulations of this vaccine have been tested against live
sporozoite challenge in volunteers, with the highest protect-
ive efficacies (30–50%) observed with an adjuvant contain-
ing monophosphoryl lipid A and QS21 (a derivative of
Quill A) [5,6]. In addition, the prime-boost regimen for the
modified vaccinia virus Ankara (MVA) and the new
fowlpox FP9 strain, both of which encode the Plasmo-
dium falciparum thrombospondin-related adhesionl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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African volunteers [7]. Asexual erythrocytic-stage vac-
cines, tested in clinical trials, also afford some degree of
protection [8]. Two asexual-stage proteins, merozoite
surface protein 1 (PfMSP1) and apical membrane anti-
gen 1, are the most extensively studied candidates for
the development of erythrocytic-stage vaccines [8,9].
Remarkably, all candidates for subunit vaccines against
malaria target the parasite invasion process into the
host cells. Despite the promising levels of protection in-
duced by these vaccines, none appear potent enough to
completely prevent infection in the majority of recipi-
ents. Therefore, further vaccine development research
is required to obtain the ultimate goal of complete pre-
vention of malarial infection.
Accumulating evidence shows that protective immun-
ity against liver-stage malaria parasites requires Th1-type
immune responses; these responses orchestrate optimal
CD8+ T cell-mediated cytotoxicity responses, CD8+ T
cells act as the principal effector cells for elimination of
infected hepatocytes, and induction of neutralizing anti-
bodies for trapping extracellular sporozoites [10,11].
Elimination of erythrocytic-stage parasites is dependent
on CD4+T cells; they release cytokines that activate other
effector cells to clear parasite-infected red blood cells
(pRBCs) and maintain protective antibody production.
The mechanisms by which antibodies are effective in-
clude blockading the invasion of free merozoites into
RBCs and cytophilic antibody-dependent cellular killing
[12]. Therefore, ideal vaccines for pre-erythrocytic and
erythrocytic-stage malaria should induce a protracted
Th1 memory response coupled with a sufficiently robust
parasite-neutralizing antibody response [12,13]. Such re-
sponses are achievable using appropriate immunization
regimens in conjunction with novel adjuvants and vac-
cine delivery vehicles [14].
Oligomannose-coated liposomes (OML) are a novel
adjuvant capable of inducing Th1 immune responses
and cytotoxic T lymphocytes (CTLs) specific for the
encased antigen. OMLs are taken up preferentially by
phagocytic cells, such as dendritic cells and macro-
phages, through mannose-binding lectin receptors and
complement receptor type 3, which leads to antigen-
presenting cell (APC) maturation, expression of co-
stimulatory major histocompatibility complex (MHC)
class I and II molecules, and migration of APCs into
lymphoid tissues from peripheral tissues. Consequently,
APCs introduce the encapsulated protein to CD4+ and
CD8+ T cells, which generate encased-antigen-specific
Th1 cells and CTL responses in the host [15,16]. Indeed,
the protective effects of OML-based vaccines have been
reported for a variety of protozoan infections, including
those caused by Neospora caninum, Leishmania major
and Toxoplasma gondii [17-21]. In the present study, theprotective effects of immunization with OML-entrapped
C-terminal-merozoite surface protein 1 (OML-PbMSP1)
and truncated circumsporozoite protein (OML-PbCSP)
against Plasmodium berghei merozoite and sporozoite
challenge in BALB/c mice were investigated. The trun-
cated regions of each antigen used for OML encapsulation
were designed based on the earlier vaccination trials with
protective effects or their role in host cells invasion [22].
Moreover, truncated region of PbCSP was designed based
on the target region of RTS,S vaccine containing CD8 epi-
topes and repeat region of CSP [5,23]. The present study
revealed that the OML-PbCSP immunization regimen
conferred a significant degree of protection against the
pre-erythrocytic stage of P. berghei.
Methods
Ethics statement
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of Ministry of Education, Culture,
Sports, Science and Technology, Japan. The protocol was
approved by the Committee on the Ethics of Animal Ex-
periments of the Obihiro University of Agriculture and
Veterinary Medicine (Permit number 24–17, 25–66). All
surgery was performed under isoflurane anesthesia, and
all efforts were made to minimize animal suffering.
Mice
Seven-week-old BALB/c mice purchased from Clea
(Tokyo, Japan) were housed under specific-pathogen-free
conditions in the animal facility of the National Research
Center for Protozoan Diseases at Obihiro University of
Agriculture and Veterinary Medicine, Obihiro, Japan. All
mice used in the present study were treated under the
guiding principles for the care and use of research animals
promulgated by Obihiro University of Agriculture and
Veterinary Medicine.
Parasites
Plasmodium berghei (ANKA strain) was obtained from
the Department of Molecular Parasitology, Ehime Univer-
sity School of Medicine, Japan and maintained by mos-
quito transmission in Anopheles stephensi interspersed by
a maximum of two serial passages in BALB/c mice. The
pRBCs were recovered from frozen pRBC stock by intra-
peritoneal (i.p.) passage inoculations in mice. Sporozoites
were obtained by dissection of salivary glands from P.
berghei-infected female mosquitos 21 days after taking
blood meals from P. berghei infected mice.
Recombinant proteins and liposome preparation
Recombinant proteins comprising truncated regions of
PbMSP1 (Leu1609-Ser1768, GenBank accession number:








Figure 1 Expression and purification of recombinant proteins.
15% sodium dodecyl sulphate polyacrylamide electrophoresis gel
(SDS-PAGE) for recombinant proteins stained with Coomassie blue.
Lanes: M, molecular mass marker; lane 1, PbMSP1; lane 2, PbCSP.
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glutathione S-transferase (GST) fusion proteins. Briefly, the
coding regions of the targeted genes were amplified from P.
berghei ANKA genomic DNA with specific primer sets de-
signed from the GenBank sequences: these were 5’-AC
GGA TCC AGT ATT ACC ACC GAG CAG AA-3’, which
includes a BamHI restriction enzyme site (boldface), and 5’-
AG CTC GAG TTA GCT GGA AGA GCT ACA GAA-3’,
which includes a XhoI restriction enzyme site (boldface) for
PbMSP; and 5’-AA GGATCC CAG CCA CAA CCA CAG
CCA GGT-3’, which includes a BamHI restriction enzyme
site (boldface), and 5’-GG CTC GAG TTA TGA ACATTT
ATC CAT TTT-3’, which includes a XhoI site (boldface) for
PbCSP. PCR products were digested with the appropriate
restriction enzymes and then ligated into a pGEX-4 T1 (GE
Healthcare, Buckinghamshire, UK) expression vector, which
had been digested with the same set of restriction enzymes.
The nucleotide sequences of the PbMSP1- and PbCSP-
positive plasmid inserts were determined using an ABI 3100
DNA sequencer (Applied Biosystems, Foster City, CA,
USA). Recombinant proteins were expressed in large-scale
DH5α strain E. coli cultures (Takara Bio Inc., Osaka, Japan)
and purified by Glutathione-Sepharose 4B beads (GE
Healthcare). Purified recombinant proteins were treated
with thrombin protease (GE Healthcare) to digest the GST
tag and then subjected to endotoxin removal using the
membrane filter, Acrodisc® Unite (Pall Life Sciences, Ann
Arbor, MI, USA). The purity and quantity of the recombin-
ant proteins were tested by sodium dodecyl sulphate poly-
acrylamide gel electrophoresis (SDS-PAGE) stained with
Coomassie Brilliant Blue R250 (MP Biomedicals Inc.,
Illkirch-Graffenstaden, France) and by a BCA protein assay
kit (Thermo Fisher Scientific, Inc. Rockford, IL, USA). Sin-
gle bands (20-kDa and 14-kDa) corresponding to each re-
combinant protein (PbMSP-1 and PbCSP, respectively)
were observed with SDS-PAGE (Figure 1). Thereafter,
OMLs were prepared for recombinant protein entrapment
as described previously [17-21], and the amount of en-
trapped antigen was measured using a modified Lowry
protein assay reagent (Pierce, Rockford, IL, USA).
Immunization and challenge infections
Seven-week-old female BALB/c mice were immunized
subcutaneously (s.c.) with 3 μg of OML-PbMSP1 or
OML-PbCSP. In parallel, the other groups of mice were
immunized with 3 μg of the corresponding naked protein,
or OML alone. Two boosts with the same dose of protein
were administered s.c. at 14-day intervals. In separate ex-
periments, modified immunization regimens that included
boosting once before infection and immunization with
1 μg of OML-PbCSP were performed. In all experiments,
each mouse received a 100 μl immunization, adjusted by
adding phosphate-buffered saline (PBS). Serum samples
(15 μl) were serially obtained from the tail vein of eachmouse at 0, 14, 28 and 42 days post-1st immunization.
The specific reactivity of immune sera was confirmed by
using indirect fluorescence assay with pRBCs or purified
sporozoites. Thereafter, mice immunized with PbMSP1
were infected with an intraperitoneal (i.p.) inoculation of
1 × 105 fresh pRBCs, while mice immunized with PbCSP
were infected s.c. (into the loose skin over the neck and
shoulders) with a live inoculum of 2 × 103 sporozoites/
mouse 14 days after the last boost. Parasitemia and sur-
vival rates were monitored over a 30-day period.
Measurement of antigen-specific antibodies
An enzyme-linked immunoabsorbent assay (ELISA)
was performed to examine the immunogenicity of the
immunization regimen as described previously [18,20,21].
Briefly, 50 μl of purified antigen (at a final concentration
of 0.1 μM) was coated onto a 96-well microtiter plate
(Nunc, Roskilde, Denmark) and incubated overnight at 4°C
with a carbonate-bicarbonate buffer (pH 9.6). Plates were
blocked with 100 μl of PBS-3% skimmed milk (3% SM-
PBS) per well and then incubated at 37°C for 1 h with 50
μl of each serum sample diluted 1:100 or serially diluted
from 1:100 to 1:51,200 in 3% SM-PBS. After washing six
times with PBS containing 0.05% Tween 20, the plates
were incubated at 37°C for 1 h with horseradish
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(Bethyl Laboratories, Montgomery, TX, USA) diluted in
3% SM-PBS to 1:4,000. Thereafter, the plates were
washed with 100 μl substrate solution (0.1 M citric
acid, 0.2 M sodium phosphate, 0.003% H2O2), and 0.3
mg/ml 2,2’-azide-bis [3-ethylbenzthiazoline-6-sulfonic
acid] (Sigma St. Louis, MO, USA) was added to each
well. The mean optical density (OD) of the wells was
determined by measurement at a wavelength of 415 nm
using an MTP-500 microplate reader (Corona Electric,
Tokyo, Japan). Endpoint titers were expressed as the recip-
rocal of the highest sample dilution for which the OD was
equal or greater than the cut-off values calculated based
on the average ODs of the pre-immune mouse sera plus
three standard deviations.
In vitro splenocyte stimulation assays
Spleens were harvested 14 days after the last booster,
and a single-cell suspension of splenocytes was plated
into 96-well microplates at 5 × 105/200 μl/well in RPMI
1640 medium (Sigma) supplemented with 5% foetal bo-
vine serum [18,21]. Cultures were stimulated by adding
10 or 50 μg/ml of purified PbCSP, or 0.5 μg/ml of conca-
navalin A. After incubation for 48 h at 37°C, the culture
supernatants were collected and assayed for IFN-γ, IL-4
and IL-10 production using commercial ELISA kits
(Pierce Biotechnology, Rockford, IL, USA), according to
the manufacturer’s instructions.
Statistical analysis
The significant differences among the means of all vari-
ables were examined by a one-way analysis of variance
followed by Tukey’s multiple comparison test (GraphPad
Prism 5, GraphPad Software Inc., San Diego, CA, USA).
Results were considered to be statistically significant
when p was <0.05.
Results
Immunization with OML-PbMSP1 prolonged survival but
fails to protect mice from erythrocytic-stage challenge
infection with Plasmodium berghei
To evaluate the immunogenicity of the OML-PbMSP1
immunization, sera were serially sampled prior to and after
each immunization, and the antibody responses were ex-
amined by ELISA using PbMSP1. Of note, OML-PbMSP1
induced highly specific antibody responses in the mice
consisting of IgG1 and IgG2a isotypes (Figure 2A,B).
Indeed, the PbMSP1-specific antibodies induced by
immunization with OML-PbMSP1 were significantly
greater than those induced by naked antigen over the
course of the immunizations, and it was found that the ti-
ters increased at least 10-fold after the third immunization
(Table 1 and Figure 2A,B). No PbMSP1-specific antibody
responses were detected in mice that received OML or noimmunization. Thereafter, to evaluate the protective effi-
cacy of OML-PbMSP1 against erythrocytic-stage infection,
mice were infected with pRBCs and their parasitemia and
survival rates were monitored over a 30-day period. Mice
showed a patent parasitemia by day 3 post-infection
and succumbed to malaria infection within one month
(Figure 2C,D). Notably, the OML-PbMSP1-immunized
mice had a delay in their onset of parasitemia (36.4%,
4/11 mice) and prolonged survival as compared with
the other groups of mice (Table 1).
Immunization with OML-PbCSP confers substantial
protection against liver-stage Plasmodium berghei infection
The immunization regimen with either OML-PbCSP
(3 μg) induced strong and specific antibody responses to
the antigen, which consisted of IgG1 and IgG2a isotypes
(Figure 3A-B). Antigen-specific IgG1 and IgG2a were
significantly greater in mice immunized with OML-
PbCSP than in mice immunized with the corresponding
naked antigen over the course of the immunizations
(Figure 3A-B). No specific-PbCSP antibody responses
were observed in mice that received OML or no
immunization. Consistently, antibody titration against
antigen revealed that the IgG1 and IgG2a titers in-
creased at least 20-fold and 16-fold, respectively, in the
OML-based antigen-immunized mice as compared with
those that received the corresponding naked antigen
(Table 2). These results showed that the immunization
regimen for OML-PbCSP was capable of inducing ro-
bust humoral responses consisting of IgG1 and IgG2a
isotypes. Next, immunized mice were infected s.c. with a
live inoculum of 2 × 103 sporozoites/mouse 14 days after
their last boost, after which their parasitemia and sur-
vival rates were monitored over a 30-day period. Not-
ably, 54% of the OML-PbCSP-immunized mice showed
complete sterile protection, as defined by the absence of
patent parasitemia over the study period. In contrast, the
OML-immunized control group showed 9.1% protection
(Table 2). No protection was observed in the mice that
received the naked antigen immunization regimen or no
immunization (Table 2). Moreover, comparison of the para-
sitemia curves revealed that the OML-antigen-immunized
mice, which had pRBCs, experienced at least a 1-day delay
in the onset of parasitemia as compared with mice immu-
nized with naked antigen or OML alone, or those that were
not immunized (Table 2). Moreover, antibody titer of anti-
PbCSP-specific IgG2a in protected mice by OML-
PbCSP immunization tended to be higher than those
in susceptible mice received same immunization (pro-
tected; 3520 ± 787, unprotected; 1733 ± 1753, P = 0.0504),
while there was no significant difference in the antibody
titer of the specific IgG1. Furthermore, use of a modified
immunization regimen comprising OML-PbCSP with a
single boost resulted in a reduced protection rate as noted









































































































Figure 2 Efficacy of immunization with OML-PbMSP1. ELISA detection of antigen-specific IgG1 (A) and IgG2a (B) in mice immunized with
recombinant PbMSP1 over the course of immunization. The mean optical density (OD) was determined at a wavelength of 415 nm. Each bar
represents the mean ± SD for used mice per group and results are representative of two independent experiments. Different superscript letters
indicate statistically significant differences (P <0.05) among groups at each time-point as determined by a one-way analysis of variance
followed by Tukey’s multiple comparison test. Parasitemias (C) and survival rates (D) after challenge infection with pRBCs. Each bar represents
the mean ± SD for 11 mice per group (only 6 mice for PbMSP1) and results are from two pooled independent experiments. Mice were either
immunized by OML-PbMSP1 (OML-PbMSP1), OML alone (OML-PBS), or naked PbMSP1 (PbMSP1), or not immunized (None).
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PbCSP containing 1 μg antigen with two boots resulted in
66.7% complete protection in mice. Nonetheless, lower
protection correlated with reduced antibody responses
was observed in OML-PbCSP-immunized mice with single
boost (Table 2). These results show that the immunization
regimen with OML-PbCSP conferred a significant degreeTable 1 Effects of OML-PbMSP1 immunization against P. berg
Immunization Antibody titration* In
IgGl IgG2a
OML-PbMSP1 11636 ± 5593†† 2182 ± 1604††
PbMSP1 1333 ± 413 283 ± 132
OML-PBS 0 0
None 0 0
*Antigen-specific 1gG1 and IgG2a detected by ELISA with recombinant PbMSP1 at
antibody ± SD per mouse group.
*Each value represents the average survival day ± SD per mouse group.
†Mice were scored as protected when parasitemia was not observed over a 30-day
††Indicates statistically significant differences between the antibody titers of OML-P
naked antigen.
Results represent pooled data of two independent experiments.of protection against pre-erythrocytic stage infection of P.
berghei in the BALB/c mice.
Additionally, to gain better insight into the cellular
responses induced by the immunization regimen with
OML-PbCSP, splenocytes were prepared from immunized
mice and stimulated in vitro for cytokine detection. Strik-
ingly, splenocytes from the OML-PbCSP-immunized micehei merozoite challenge
fected/total [lst +2nd trials] Survival* Protection†
(Number) (Day) (%)
11/11 [(5/5) + (6/6)] 19.1 ± 10.9 0
6/6 14.3 ± 6.7 0
11/11 [(5/5) + (6/6)] 11.3 ± 5.3 0
11/11 [(5/5) + (6/6)] 11.8 ± 5.2 0
14 days after the last boost. Each value represents the mean titer of
period.





























































Figure 3 Humoral responses in mice to immunization with OML-PbCSP. ELISA detection of antigen-specific IgG1 (A) and IgG2a (B) in mice
immunized with recombinant PbCSP. The mean optical density (OD) was determined at a wavelength of 415 nm. Each bar represents the mean ± SD
for used mice per group and results are representative of two independent experiments. Different superscript letters indicate statistically significant
differences (P <0.05) among groups at each time-point as determined by a one-way analysis of variance followed by Tukey’s multiple comparison test.
Mice were either immunized by OML-PbCSP (OML-PbCSP), OML alone (OML-PBS), naked PbCSP (PbCSP) or not immunized (None). Different superscript
letters indicate statistically significant differences (P <0.05) among groups as determined by a one-way analysis of variance followed by Tukey’s multiple
comparison test.
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at concentrations of 10 μg/ml or 50 μg/ml (Figure 4A). In
contrast, the IFN-γ levels of the splenocytes from OML- or
naked PbCSP-immunized mice as well as non-immunized
mice after stimulation with the same antigen were below
the limits of detection of the kits. Likewise, IL-4 was de-
tected in cultures from the antigen-immunized mice after
stimulation with 50 μg/ml PbCSP (Figure 4B). However,
detected IL-4 levels in OML-PbCSP-immunized mice
were significantly higher than those detected in naked
antigen immunized mice (Figure 4B). Levels of IL-10 were
not significantly different in all cultures after stimulation
with 50 μg/ml PbCSP (Figure 4C). Stimulation with con-
canavalin A, which acted as a positive control, resulted in
high levels of IFN-γ, IL-4 and IL-10 in all of the cultures
(Figure 4).Table 2 Effects of OML-based antigen immunization against P
Antigen Immunization Antibody titration*
Dose Boost IgG1 IgG2a
OML-PbCSP 3 μg 2 10666.7 ± 3304.9†† 3466.7 ± 1573.1†
1 μg 2 4900.0 ± 2038.6†† 1200.0 ± 979.8†
OML-PbCSP 3 μg 1 1733.3 ± 786.5†† 600.0 ± 219.1††
1 μg 1 533.3 ± 206.6†† 266.7 ± 103.3††
PbCSP 3 μg 1 433.3 ± 196.6 166.7 ± 51.6
OML-PBS 2 0 0
None 0 0 0
*Antigen-specific IgG1 and IgG2a detected by ELISA with recombinant PbCSP l4 da
mouse group.
*Each value represents tie mean day of parasitemia onset ± SD per mouse group.
††Indicates a statistically significant difference between the antibody response of th
immunized with naked antigen.
†Mice were scored as protected when parasitemia was not observed over a 30-day
†Significant difference in protection rate as compared to none and as calculated by
Results represent pooled data of two independent experiments.Discussion
In general, protection against erythrocytic-stage infection
is thought to be mediated by CD4+ T cells, which orches-
trate the activation of effector cells and maintain the pro-
duction of protective antibodies. Humoral responses have
been shown to play an indispensable role in protection
against malaria by blocking merozoite invasion and neu-
tralizing pRBCs for macrophage phagocytosis [24,25].
However, subunit vaccine failure against P. berghei
erythrocyte-stage parasite challenge has often been ob-
served [26,27], with only a few trials showing some degree
of protection in mouse model [22,28]. The difficulties in
achieving protection against P. berghei might be caused by
suppression or evasion of the immune system during the
infection. In fact, alongside the sequestration of parasites
in blood capillaries, erythrocytic-stage P. berghei can. berghei sporozoite challenge
Infected/total
[1st + 2nd trials] (Number)
Parasitemia* Protection† (%)
† 5/11 [(2/5) + (3/6)] 6.40 ± 0.55 54% (P = 0.004)
† 2/6 8.50 ± 2.10 66.7% (P = 0.002)
5/6 6.50 ± 1.00 66.7% (P = 0.002)
4/6 6.60 ± 1.34 33.3% (P = 0.041)
11/11 [(5/5) + (6/6)] 5.83 ± 0.98 0% (N.A.)
10/11 [(5/5) + (5/6)] 5.50 ± 1.40 5.9% (P = 0.413)
11/11 [(5/5) + (6/6)] 5.09 ± 1.04 0%
y after the last boost. Each value represents the mean antibody titer ± SD per
e OML-based antigen-immunized group to those of the corresponding group
pariod.









































































Figure 4 Cytokine detection in splenocyte cultures. To detect IFN-γ (A), IL-4 (B) and IL-10 (C) production by ELISA, splenocyte cultures for each
group of mice (n = 4) were prepared and the supernatants were collected after incubation for 48 h at 37°C with the PbCSP antigen (10 or 50 μg/ml),
0.5 μg/ml of concanavalin A (ConA) or without any stimulus. Each bar represents the mean ± SD based on four mice per group. Mice were either
immunized by OML-PbCSP (OML-PbCSP), OML alone (OML-PBS), naked PbCSP (PbCSP), or not immunized (None). Different superscript letters
indicate statistically significant differences (P <0.05) among groups as determined by a one-way analysis of variance followed by Tukey’s
multiple comparison test.
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malarial antigens by APCs, thereby preventing the devel-
opment of protective immunity in vaccinated mice
[27,29]. A recent study has shown that vaccination of mice
with recombinant P. berghei schizont egress antigen-1
(PbSEA-1) significantly reduces parasitemia and delays
mortality. The authors have concluded that the protection
by PbSEA-1 is due to the function of its specific antibody
that decreases the parasite replication by arresting schiz-
ont and preventing the egression [30]. In the present
study, immunization with OML-PbMSP1 prolonged sur-
vival but failed to protect mice against the infection with
erythrocytic-stage P. berghei. However, immunizations
with the OML-PbMSP1 induced the production of anti-
PbMSP1 IgG1 and IgG2a, which recognized the parasites.
Thus, a possibility for lack of protection in this data may
be due to the insufficient antibody titer against the para-
site infection.
Sterile protection induced by an effective malaria vac-
cine should lead to the blockade of exoerythrocytic
forms retained within hepatocytes and trapped by
Kupffer cells, whereas activated CTLs act as effector cells
for the elimination of parasitized hepatocytes in the liver
[9,10]. Moreover, CD4+ T cells seem to contribute to
protective immunity in the liver through initiating the
responses of CD8+ T effector cells and mediating the
production of neutralizing antibodies [31]. Sporozoite-
specific antibodies may neutralize malaria parasites and
inhibit their invasion into hepatocytes, thereby allow-
ing macrophages and other polymorphonucleocytes to
phagocytize extracellular sporozoites [9,10]. In addition,
a recent study has shown that sporozoite-specific anti-
bodies are protective and provide sterilizing immunity
against malaria infection when reaching or exceeding a
critical plasma concentration [32]. In the present study,
immunization with OML-based sporozoite antigen in-
duced high humoral responses consisting of IgG1 and
IgG2a, and the splenocyte cultures from the OML-
PbCSP-immunized mice released the production of
IFN-γ, IL-4 and IL-10 after stimulation with the PbCSP.
These results support the concept that OML has adju-
vant properties through triggering humoral and cellular
responses [15-21]. Strikingly, immunization with OML-
PbCSP elicited substantial protection in mice against
sporozoite challenge infection. The protection conferred
by s.c. immunization with OML-PbCSP may be related
to activation of professional APCs by OML; these cells
might effectively present PbCSP-derived peptides via
MHC class I and class II molecules, which prime specific
CD8+ and CD4+ memory T cells, respectively [15]. Thus,
effector memory T cells may migrate into the liver and
trigger local CTLs that eliminate parasitized hepatocytes
following challenge infection with sporozoites. In paral-
lel, PbCSP-specific antibodies might inhibit sporozoiteinvasion and mediate the clearance of parasites by anti-
body-dependent-cellular-cytotoxicity. Indeed, the present
data revealed some correlation between the protection
and the antibody response to PbCSP as evidenced by ele-
vated antibody titers in protected mice over unprotected
received same immunization regimen.
Nonetheless, the protection rates observed in the
present data were comparable to those in several other
immunization trials using murine models of infection.
For instance, immunization with the long synthetic poly-
peptide, PbCSP242–310, coupled with the QS-21 saponin
adjuvant resulted in a 60% level of protection [23]. Ad-
ministration of recombinant adenylate cyclase toxoid of
Bordetella pertussis containing a PbCSP epitope elicited
a robust IFN-γ-producing T cell response also associated
with 60% protection in mice in the absence of further
adjuvant [33]. Additionally, immunization with the repeat
epitope of PbCSP and different oil-based adjuvants elicited
29–100% sterile protection in mice [34]. Genetic vaccin-
ation with PbCSP induced 30–90% protection in mice
against sporozoite and mosquito challenge infections [35].
Likewise, prime-boost vaccinations of the attenuated re-
combinant poxviruses MVA and FP9 encoding CSP or
thrombospondin-related adhesion protein of P. berghei,
respectively, were shown to confer substantial protection
(20–90%) against liver-stage murine malaria [7,36].
OMLs are preferentially incorporated into macrophages
via ICAM-3 grabbing nonintegrin-related 1 (SIGNR1)
[15,37,38]. Furthermore, the macrophages and DCs also
produce IL-12 in response to the preferential uptake of
OMLs, leading to antigen-specific Th1 immunity [39].
Thus, the uptake of antigen-encapsulating OMLs by APCs
must be an initial key event in the induction of the antigen-
specific Th1 immune response. OMLs could be defined as
good adjuvant that enhanced the immunogenicity of anti-
genic vaccine components. In addition, OMLs are very suit-
able for use as an adjuvant and vehicle for vaccines because
they consist of innocuous materials distributed ubiquitously
throughout the body and cause no damage to the skin at
the injection site [40]. To develop novel type of malaria
vaccine, there is a need to evaluate the enhanced protection
of OML-based vaccine by using appropriate adjuvant such
as alum, cocktail antigens or synthetic peptides formation.
Conclusions
Immunization with OML-PbCSP elicited substantial
protection against liver-stage malaria infection in BALB/c
mice. The current approach has potential to provide a
novel antigen-delivery system for developing malaria
vaccine.
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